We design and apply unique patient-based cellular assays for large-scale phenotypic screening, leaning on the power of AI-driven image analysis. Integrated from bed to bench and back to bed, we aim to generate most efficient first-in-class therapeutic molecules for next generation medicine.
Expertise
From patient-based disease models to novel therapeutic molecules.
Pipeline
Innovation holds the key. Our pipeline of drug discovery programs.
Partner with us
Initiate, codevelop or support our discovery programs.
Newsroom
Keep posted about
our latest developments
and achievements
New publication: The JUMP Cell Painting dataset, studying the morphological impact of 136,000 chemical and genetic perturbations goes public
Since 2019, Ksilink has been part of the JUMP-Cell Painting Consortium, a collaboration between 10 pharmaceutical companies, six supporting technology companies, and two...
Meet us at Santa Fe Keystone Symposia on Feb. 13th & 14th, 2023!
Discover how Ksilink, myriamed and their spin-off Myrtil Biotechnologies implement deep learning to enhance high-content screening and deep-tissue phenotyping to identify...
New publication: Machine learning-aided analysis of human dopaminergic neurons
Link to publication: https://www.cell.com/stem-cell-reports/fulltext/S2213-6711(22)00423-4 In our most recent work in collaboration with colleagues from Life & Brain and the...
They trust us
“Patient-derived disease models used for phenotypic drug discovery purposes carry a huge potential. We strongly believe in Ksilink as a key player for effectively bridging the gap between scientific excellence and the pharma industry.”
Jacques Volckmann, Head of R&D, Sanofi, France
“Ksilink’s capacities to apply patient-derived disease models for high-throughput, high-content screening by using AI-driven deep learning computation is outstanding.”
Wolfram Zimmermann, CSO, Myriamed GmbH, Germany
“Bridging the gap between academic clinical research and industry is key to enable the precision medicine of tomorrow. We see big value in the ability of Ksilink to translate clinical expertise into treatment for diseases with high unmet medical need .”
Andreas Meyer-Lindenberg, Director and CEO, Central Institute of Mental Health, Germany
“Phenotypic screening using most authentic disease models is clearly paving the way towards next generation medicine. We strongly believe in Ksilink’s potential, allowing the generation of valuable first-in-class therapeutic molecules.”
Bert Klebl, Managing Director of Lead Discovery Center, Germany